The authors reported that people aged ≥65 years constitute the majority of those diagnosed with cancer, yet they remain proportionally underrepresented in research at every stage of the care pathway. The piece is framed as a manifesto: a direct appeal that research cannot be complete if older adults are excluded. The article does not present new trial data; instead, it synthesizes existing literature and expert opinion to make a policy-focused argument.
Short, direct statements are repeated throughout the commentary. Older adults are central to cancer incidence. The cohort of older patients is getting larger globally, according to the references cited by the authors. However, concrete trial enrollment figures, percentages of representation, or numeric enrollment targets were not reported in the preview text made available to readers without subscription access.
The authors called on four groups by name: funders, regulators, researchers and journals. They urged these stakeholders to make the systematic inclusion of older adults the norm. The article sets this as a responsibility shared across the ecosystem of cancer research — not the sole remit of individual investigators.
Investigators reported that this call spans the full research continuum: prevention studies, interventional and observational trials, and end-of-life research. The authors argued for changes to policy and practice that would reduce the systematic exclusion of older people, though specific regulatory mechanisms or funding mandates were not detailed in the preview content.
The article cites population-based and burden-estimate studies to contextualize the problem. References include global incidence and burden estimates in older adults, work on modifiable risk factors for cancer burden, and analyses of global research funding distributions. The authors also referenced systematic reviews and historic studies that describe barriers to trial participation among older patients.
Specifically, prior literature cited by the authors documented barriers and interventions for older adult participation in clinical trials, and older-adult–focused guidance on pragmatic trial strategies was included among the references. The commentary used these published works as the evidence base for the manifesto. The preview did not contain methodological details, individual study sample sizes, or trial endpoints beyond what was available in the referenced citations.
The commentary referenced recent working-group guidance on pragmatic strategies for trial designs and endpoints in older adults with cancer. The authors noted that tailored designs and appropriate endpoints are important to evaluate interventions in older populations. The preview did not describe specific designs, endpoints, dosing recommendations, or operational protocols; those details were not included in the publicly viewable excerpt.
Authors observed that both structural barriers (for example, funding priorities and regulatory frameworks) and patient-level barriers (documented in prior studies) contribute to underrepresentation. The article urged adoption of pragmatic strategies, as previously proposed by multidisciplinary groups, to align trial design with the needs and realities of older adults with cancer.
The published piece included author affiliations across institutions and declared no competing interests. The authors acknowledged use of an AI language model for language editing; they stated that the tool assisted with flow, clarity and readability, while all content, data and references were reviewed and verified by the authors themselves. The article also provided an acknowledgements statement indicating funding support for one author.
Readers encountering the preview on the journal website may find that full access requires subscription or institutional access; the preview explicitly referenced access options and purchase paths. The publicly available excerpt did not include the full text of the manifesto nor operationalized policy proposals.
Limitations and unanswered questions documented in the article
The commentary is an expert manifesto rather than a primary research report; it therefore does not provide new trial data, enrollment metrics, or experimental outcomes. The preview text did not provide specific regulatory policy language, concrete funding mechanisms, or numerical targets for inclusion of older adults. Those details, if present in the full article, were not accessible in the preview. The article ends on calls to action and references to guidance and prior literature, leaving specific implementation strategies and regulatory steps as topics for further development and stakeholder engagement.